The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company plans to enter the EU markets in FY22
The company is working closely with its six manufacturing partners in India
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
